Logos Global Management LP Verve Therapeutics, Inc. Transaction History

Logos Global Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$11.42 - $20.82 $2.46 Million - $4.48 Million	215,000 New	215,000 $2.85 Million
Q2 2022 Aug 15, 2022	SELL	$11.14 - $23.17 $1.08 Million - $2.25 Million	-96,912 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$20.92 - $39.36 $7.25 Million - $13.6 Million	-346,353 Reduced 78.14%	96,912 $2.21 Million
Q3 2021 Nov 15, 2021	SELL	$46.0 - $73.99 $14.5 Million - $23.3 Million	-315,000 Reduced 41.54%	443,265 $20.8 Million
Q2 2021 Aug 16, 2021	BUY	$31.92 - $60.25 $24.2 Million - $45.7 Million	758,265 New	758,265 $45.7 Million

182

73.3M

85K

215K

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $456M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

Get notified when there are updates to the investment portfolio of Logos Global Management LP, based on Form 13F filings with the SEC.

Stay updated on Logos Global Management LP with notifications on news.